Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cervarix vs Gardasil 2-Dose Schedules in 9-14 Year Old Females
NCT01462357Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2011
- Primary completion
- Oct 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 3 trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection, sponsored by GSK. Started Nov 2011; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT01462357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01462357.